Royalty Report: Drugs, Pharmaceuticals, Disease – Collection: 28000

$100.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 3

Primary Industries

  • Drugs
  • Pharmaceuticals
  • Disease
  • Therapeutic
  • cardiac

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 28000

License Grant
The Licensor granted an exclusive option to license its product candidate, TRV027. If Licensee exercises this option, the license agreement will become effective and Licensee will have an exclusive worldwide license to develop and commercialize TRV027 and specified related compounds.  The Licensor is about to conduct a Phase 2b trial of TRV027 in acute heart failure.
License Property
TRV027 is an intravenous drug for the treatment of acute heart failure (AHF) in combination with standard diuretic therapy, and is currently being investigated in a Phase 2 clinical trial.

IPSCIO Record ID: 28684

License Grant
The Licensor is developing a cell therapy for the treatment of cardiovascular disease.

The Merger Agreement requires the Licensee to pay certain earn out payments following the first commercial sale of AMR-001 for the benefit of the former stockholders of the Licensor.

License Property
The Licensor's lead compound, AMR-001, now represents the Licensee's most clinically advanced therapeutic and has commenced enrollment for a Phase 2 trial to investigate AMR-001’s efficacy in preserving heart function after a heart attack.
Field of Use
The Licensee also expects to begin a Phase 1 clinical trial by 2013 to investigate AMR-001’s utility in arresting the progression of congestive heart failure and the associated comorbidities of that disease.

IPSCIO Record ID: 7446

License Grant
The Licensor hereby grants to the Licensee, upon the terms and conditions, an exclusive, nontransferable royalty-bearing, commercial License in the territory under the Licensed Patent Rights for the purpose of making, having made, using, offering to sell, selling and importing Licensed Product(s) in the Field of Use and for granting subLicenses.
License Property
Licensed Patents:
12/775,641 Use of Pyridoxamine to treat and/or prevent disears processes
12/384,902  Methods of using Pyrisocamine as a radioprotector
12/384,832  Methods of using Pyridoxamine for treating adverse health effects of chemotherapy or  effects of chemotherapy
61/508466  Methods for treating Inflammation
Field of Use
The field of use includes therapeutic applications of pyridoxamine in acute renal failure, acute renal injury, as a radiation-protectant and a chemotherapy-protectant.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.